Agree.
With the prior announcement falling prior to the halt, has to looking positive.
Appointment of Dr Tony Keating as Executive Director & Resignation of Dr Tom Young Highlights: • Appointment of Dr Tony Keating as part time Executive Director, effective 29 July 2024
•Dr Keating brings extensive experience as a healthcare executive, having co-founded ResApp Health and led it through commercialisation, culminating in a $180m acquisition by global biopharmaceutical company Pfizer in 2022
• Along with his track record in commercialising AI-based digital health technology, Dr Keating brings advanced knowledge of the US regulatory landscape and strong networks in the global healthcare industry
• Appointment strengthens the composition of the Board ahead of pending results of TRI’s comprehensive Phase 2 SAMDE study for TrivarX’s proprietary MEB-001 algorithm which assists with the effective screening of a current Major Depressive Episode (cMDE)
• Resignation of Dr Thomas Young as Non-Executive Director, effective 29 July 2024
Agree.With the prior announcement falling prior to the halt, has...
Add TRI (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.6¢ |
Change
0.000(0.00%) |
Mkt cap ! $16.45M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 710619 | 3.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.6¢ | 19000 | 1 |
View Market Depth
| Last trade - 16.12pm 29/07/2024 (20 minute delay) ? |
| TRI (ASX) Chart |
Day chart unavailable